Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01703286 |
Recruitment Status
:
Completed
First Posted
: October 10, 2012
Results First Posted
: January 19, 2015
Last Update Posted
: January 19, 2015
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus. In the current trial this effect of linagliptin treatment on endothelial function will be compared against both the sulfonylurea glimepiride and against placebo, which has not been tested in a trial before; as also is the case for other DPP-4 inhibitors.
Besides placebo, glimepiride was chosen as a comparator, as it is one compound of the second most used oral antidiabetic drug class.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetes Mellitus, Type 2 | Drug: Placebo Drug: Linagliptin Drug: Glimepiride | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 42 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA') |
Study Start Date : | October 2012 |
Actual Primary Completion Date : | January 2014 |
Actual Study Completion Date : | January 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Linagliptin 5mg
given once daily over 28 days
|
Drug: Placebo
Placebo matching Glimepiride
Drug: Linagliptin
given once daily for 28 days
|
Active Comparator: Glimepiride
given once daily in 1mg dosis over 7 days, following a titration step to 2mg and application for 21 days
|
Drug: Placebo
Placebo matching Linagliptin
Drug: Glimepiride
1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
|
Placebo Comparator: Placebo
given once daily over 28 days
|
Drug: Placebo
Placebo matching Linagliptin
Drug: Placebo
Placebo matching Glimepiride
|
- Change From Baseline in Flow Mediated Vasodilation (FMD) Under Fasted Condition on Day 28 [ Time Frame: baseline and day 28 for each treatment arm ]Endothelial function under fasted condition was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
- Change From Baseline in Flow Mediated Vasodilation (FMD) 2 h Post Meal on Day 28 [ Time Frame: baseline and day 28 for each treatment arm ]Endothelial function 2 hours post meal was measured with flow mediated vasodilation (FMD). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
- Change From Baseline in 2 Hours Post Meal Endothelial Independent Vasodilation (EIDV) on Day 28 [ Time Frame: baseline and day 28 for each treatment arm ]Endothelial function 2h post-meal was measured by endothelial independent vasodilation (EIDV). The change from baseline was calculated as the value on Day 28 divided by the respective value at baseline.
- Number of Patients With Adverse Events [ Time Frame: up to 20 weeks ]Number of patients with any adverse events

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
-
Type 2 diabetic male and female patients according to the following criteria:
Based upon a complete medical history and clinical laboratory tests
- Age >= 18 and Age <= 65 years
- Body mass index >= 25 <= 35 kg/m2
- HbA1c <= 7.5%
- Treatment with metformin (=1500 mg daily) for <= 3 months
-
Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation.
For female patients of childbearing potential:
- Use of acceptable method of contraception (Pearl-Index <1).
Exclusion criteria:
- Treatment with any glucose-lowering drug except for metformin within prior 3 months.
- Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance.
- Any evidence of a clinically relevant acute concomitant disease
- History of cardiovascular disease (e.g. coronary artery disease history of acute myocard infarction or stroke, peripheral vascular disease).
- History of major diabetic complications (e.g. nephropathy, retinopathy)
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, immunological or hormonal disorders (except: hypertension treated with angiotensin receptor blocker or angiotensin-converting-enzyme inhibitors, hyperlipidemia with statin therapy, thyroid hormone replacement therapy, all stable for at least three months prior to screening).
- Surgery of the gastrointestinal tract (except appendectomy).
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders.
- History of relevant orthostatic hypotension, fainting spells or blackouts.
- Chronic or relevant acute infections.
- History of relevant allergy/hypersensitivity (including allergy to drug or its excipients).
- Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial.
- Participation in another trial with an investigational drug within one month prior to administration or during the trial.
- Smoker (>= 1 cigarettes or >= 1 cigars or >= 1 pipes/day).
- Alcohol abuse (more than 60 g/day).
- Drug abuse.
- Blood donation (more than 100 mL within four weeks prior to administration or during the trial).
- Excessive physical activities (within one week prior to administration or during the trial).
- Any laboratory value outside the reference range that is of clinical relevance.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01703286
Germany | |
1218.105.001 Boehringer Ingelheim Investigational Site | |
Neuss, Germany |
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Boehringer Ingelheim |
ClinicalTrials.gov Identifier: | NCT01703286 History of Changes |
Other Study ID Numbers: |
1218.105 2012-003317-33 ( EudraCT Number: EudraCT ) |
First Posted: | October 10, 2012 Key Record Dates |
Results First Posted: | January 19, 2015 |
Last Update Posted: | January 19, 2015 |
Last Verified: | January 2015 |
Additional relevant MeSH terms:
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Glimepiride Linagliptin Anti-Arrhythmia Agents Hypoglycemic Agents Physiological Effects of Drugs |
Immunosuppressive Agents Immunologic Factors Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Dipeptidyl-Peptidase IV Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |